Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Javitt

Showing results (31-40 of 267) with videos related to

Pageof 27
Sort By:
Psychiatric Services (Washington, D.C.)|April 7, 2007
Reading disability goes beyond consent formsNadine Revheim, Daniel C Javitt
Current Opinion in Psychiatry|February 3, 2012
Glutamatergic transmission in schizophrenia: from basic research to clinical practiceJoshua Kantrowitz, Daniel C Javitt
Advances in Neurobiology|November 19, 2024
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in NeuropsychiatryJoshua T Kantrowitz, Daniel C Javitt
Scientific American|December 20, 2003
Decoding schizophreniaDaniel C Javitt, Joseph T Coyle
Schizophrenia Research|April 6, 2004
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysisUriel Heresco-Levy, Daniel C Javitt
Schizophrenia Research|February 7, 2022
The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to diseaseDaniel C Javitt, Joshua T Kantrowitz
Brain Research Bulletin|April 27, 2010
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?Joshua T Kantrowitz, Daniel C Javitt
Nature Reviews. Neuroscience|August 21, 2015
Auditory dysfunction in schizophrenia: integrating clinical and basic featuresDaniel C Javitt, Robert A Sweet
Clinical Schizophrenia & Related Psychoses|October 1, 2010
Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical modelsJoshua T Kantrowitz, Daniel C Javitt
Current Opinion in Psychiatry|April 28, 2006
Early-stage visual processing deficits in schizophreniaPamela D Butler, Daniel C Javitt
Pageof 27

Showing results (31-40 of 267) with videos related to

Sort By:
Pageof 27
Psychiatric Services (Washington, D.C.)|April 7, 2007
Reading disability goes beyond consent formsNadine Revheim, Daniel C Javitt
Current Opinion in Psychiatry|February 3, 2012
Glutamatergic transmission in schizophrenia: from basic research to clinical practiceJoshua Kantrowitz, Daniel C Javitt
Advances in Neurobiology|November 19, 2024
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in NeuropsychiatryJoshua T Kantrowitz, Daniel C Javitt
Scientific American|December 20, 2003
Decoding schizophreniaDaniel C Javitt, Joseph T Coyle
Schizophrenia Research|April 6, 2004
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysisUriel Heresco-Levy, Daniel C Javitt
Schizophrenia Research|February 7, 2022
The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to diseaseDaniel C Javitt, Joshua T Kantrowitz
Brain Research Bulletin|April 27, 2010
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?Joshua T Kantrowitz, Daniel C Javitt
Nature Reviews. Neuroscience|August 21, 2015
Auditory dysfunction in schizophrenia: integrating clinical and basic featuresDaniel C Javitt, Robert A Sweet
Clinical Schizophrenia & Related Psychoses|October 1, 2010
Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical modelsJoshua T Kantrowitz, Daniel C Javitt
Current Opinion in Psychiatry|April 28, 2006
Early-stage visual processing deficits in schizophreniaPamela D Butler, Daniel C Javitt
Pageof 27